Idiopathic pleuroparenchymal fibroelastosis: Consideration of a clinicopathological entity in a series of Japanese patients

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Kusagaya, Hideki ^a   Nakamura, Yutaro ^a   Kono, Masato ^a   Kaida, Yusuke ^a   Kuroishi, Shigeki ^a   Enomoto, Noriyuki ^a   Fujisawa, Tomoyuki ^a   Koshimizu, Naoki ^a   Yokomura, Koshi ^a   Inui, Naoki ^a   Suda, Takafumi ^a   Colby, Thomas V ^b   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Fibroelastosis; Idiopathic interstitial lung disease; Pleural fibrosis; Pleuroparenchymal fibroelastosis

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GINGIVA TUMOR; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC PLEUROPARENCHYMAL FIBROELASTOSIS; INTERSTITIAL LUNG DISEASE; JAPANESE; LUNG BIOPSY; LUNG FUNCTION TEST; MALE; PLEURA DISEASE; PLEURA THICKENING; PLEURAL FIBROSIS; THORAX RADIOGRAPHY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; COLLAGEN; ELASTIC TISSUE; FEMALE; HUMANS; LUNG; MALE; PLEURAL DISEASES; PULMONARY FIBROSIS; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84870323541     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-72     Document Type: Article

References (19)

1. Frankel SK, Cool CD, Lynch DA, et al. Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest 2004, 126:2007-2013. 10.1378/chest.126.6.2007, 15596706.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165:277-304. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
3. Nei T, Kawamoto M, Satoh E, et al. A case of suspected idiopathic pulmonary upper lobe fibrosis (Amitani disease) with acute exacerbation. Nihon Kokyuki Gakkai Zasshi 2009, 47:116-121.
4. Morimoto A, Mochizuki Y, Nakahara Y, et al. Case of idiopathic pulmonary upper lobe fibrosis. Nihon Kokyuki Gakkai Zasshi 2010, 48:944-949.
5. Kobayashi Y, Sakurai M, Kushiya M, et al. Idiopathic pulmonary fibrosis of the upper lobe: a case report. Nihon Kokyuki Gakkai Zasshi 1999, 37:812-816.
6. Shiota S, Shimizu K, Suzuki M, et al. Seven cases of marked pulmonary fibrosis in the upper lobe. Nihon Kokyuki Gakkai Zasshi 1999, 37:87-96.
7. A case of idiopathic cavitation of lung demonstrated at the Postgraduate Medical School of London. Br Med J 1966, 1:345-348. 1843739, 4221514.
8. Undiagnosable Lung Disease. Br Med J 1962, 1:1403-1410. 1958453, 20789421.
9. Amitani RNA, Kuse F. Idiopathic pulmonary upper lobe fibrosis (IPFU). Kokyu 1992, 11:693-699.
10. Reddy TL, Tominaga M, Hansell DM, et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J 2012, in press.
11. Piciucchi S, Tomassetti S, Casoni G, et al. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. Respir Res 2011, 12:111. 10.1186/1465-9921-12-111, 3197499, 21861891.
12. von der Thusen JH, Hansell DM, Tominaga M, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol 2011, 24:1633-1639. 10.1038/modpathol.2011.114, 21822205.
13. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047. 10.1164/rccm.200404-571OC, 15665326.
14. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829. 10.1183/09031936.00005209, 19996196.
15. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769. 10.1016/S0140-6736(11)60405-4, 21571362.
16. Dosanjh A. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur J Pharmacol 2006, 536:219-222. 10.1016/j.ejphar.2006.03.007, 16581063.
17. Dosanjh A, Ikonen T, Wan B, et al. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther 2002, 15:433-437. 10.1006/pupt.2002.0367, 12406665.
18. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999, 160:1843-1850.
19. Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439-446. 10.1183/09031936.02.00081102, 11936520.